Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Amyloidosis × isatuximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 29 Neoplasms 4 Renal Insufficiency 3 Recurrence 3 Neoplasms, Plasma Cell 3 Hematologic Diseases 3 Smoldering Multiple Myeloma 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Paraproteinemias 2 Neoplasms by Histologic Type 2 Immunoglobulin Light-chain Amyloidosis 2 Blood Protein Disorders 2 Purpura 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm, Residual 1 Nausea 1 Natural Killer/T-cell Lymphoma 1 Monoclonal Gammopathy of Undetermined Significance 1 Macroglossia 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Lymphadenopathy 1 Leukemia, Plasma Cell 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Hodgkin Disease 1 Hepatomegaly 1 Hematologic Neoplasms 1 Gastrointestinal Hemorrhage 1 Diarrhea 1

Interventions

Dexamethasone 7 Cyclophosphamide 4 Bortezomib 4 Melphalan 3 Lenalidomide 3 Calcium Dobesilate 3 pomalidomide 2 Doxycycline 2 ixazomib 1 isatuximab 1 daratumumab 1 birtamimab 1 belantamab mafodotin 1 Vinorelbine 1 Thalidomide 1 Gemcitabine 1 Etoposide 1 Etanercept 1 Doxorubicin 1 Cisplatin 1 Bendamustine Hydrochloride 1 Antineoplastic Protocols 1 ARQ 197 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05066607 2024-03-06

IsAMYP

Intergroupe Francophone du Myelome

Phase 2 Unknown

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡